share_log

Novavax | 8-K: Asset Purchase Agreement

Novavax | 8-K: Asset Purchase Agreement

諾瓦瓦克斯醫藥 | 8-K:資產購買協議
美股SEC公告 ·  2024/12/04 19:07

Moomoo AI 已提取核心訊息

Novavax's subsidiary, Novavax CZ, has entered into an asset purchase agreement with Novo Nordisk Production Czech s.r.o. on December 3, 2024, to sell its biologics manufacturing campus in Bohumil, Jevany, Czech Republic. The total purchase price is $200 million, with $10 million already paid in September 2024 and another $10 million to be held in escrow for 12 months post-closing.The transaction includes the transfer of properties, moveable assets, equipment, related contracts, and certain employees. Novo Nordisk will assume associated liabilities and has agreed to reimburse Novavax CZ for operational costs up to $3.5 million per month until closing. The deal's completion is contingent upon approval from the Czech Republic's State Institute for Drug Control, with a four-month deadline for satisfying conditions.
Novavax's subsidiary, Novavax CZ, has entered into an asset purchase agreement with Novo Nordisk Production Czech s.r.o. on December 3, 2024, to sell its biologics manufacturing campus in Bohumil, Jevany, Czech Republic. The total purchase price is $200 million, with $10 million already paid in September 2024 and another $10 million to be held in escrow for 12 months post-closing.The transaction includes the transfer of properties, moveable assets, equipment, related contracts, and certain employees. Novo Nordisk will assume associated liabilities and has agreed to reimburse Novavax CZ for operational costs up to $3.5 million per month until closing. The deal's completion is contingent upon approval from the Czech Republic's State Institute for Drug Control, with a four-month deadline for satisfying conditions.
諾瓦瓦克斯醫藥的子公司諾瓦瓦克斯CZ於2024年12月3日與諾和諾德生產捷克有限公司簽署了一份資產購買協議,出售其位於捷克共和國耶瓦尼市博胡米爾的生物製品製造園區。總購買價格爲20000萬美金,其中1000萬美金已於2024年9月支付,另有1000萬美金將在交易關閉後託管12個月。該交易包括轉讓不動產、動產、設備、相關合同及某些員工。諾和諾德將承擔相關責任,並同意在交易完成前向諾瓦瓦克斯CZ報銷每月高達350萬美金的運營成本。交易的完成取決於捷克共和國藥物監管國家研究所的批准,滿足條件的截止日期爲四個月。
諾瓦瓦克斯醫藥的子公司諾瓦瓦克斯CZ於2024年12月3日與諾和諾德生產捷克有限公司簽署了一份資產購買協議,出售其位於捷克共和國耶瓦尼市博胡米爾的生物製品製造園區。總購買價格爲20000萬美金,其中1000萬美金已於2024年9月支付,另有1000萬美金將在交易關閉後託管12個月。該交易包括轉讓不動產、動產、設備、相關合同及某些員工。諾和諾德將承擔相關責任,並同意在交易完成前向諾瓦瓦克斯CZ報銷每月高達350萬美金的運營成本。交易的完成取決於捷克共和國藥物監管國家研究所的批准,滿足條件的截止日期爲四個月。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息